Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine + Cytarabine in Pediatric Refractory/Relapsed Leukemia
NCT00372619Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2007
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, open-label trial of clofarabine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and acute leukemia of ambiguous lineage (ALAL) (7 arms), sponsored by Children's Oncology Group. Primary endpoint: Overall Response Rate up to 84 days. Started Mar 2007; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT00372619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372619.